![Michael N. Avallone](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Michael N.
Avallone has been Chief Financial Officer of AMAG Pharmaceuticals, Inc. since joining the company in July 2004 and Vice President of Finance since August 2004.
From 2000 to 2004, Mr. Avallone worked at Boston Biomedica, Inc., including as Corporate Controller and Vice President of Finance and Chief Financial Officer.
He held various executive positions in accounting and finance at affiliates of NSTAR.
Eerdere bekende functies van Michael N. Avallone
Bedrijven | Functie | Einde |
---|---|---|
AMAG PHARMACEUTICALS, INC. | Financieel Directeur/CFO | 21-03-2007 |
PRESSURE BIOSCIENCES, INC. | Financieel Directeur/CFO | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
PRESSURE BIOSCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
AMAG Pharmaceuticals, Inc.
![]() AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |